Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Leases: 2020-2024

Historic Operating Leases for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $8.0 million.

  • Mirum Pharmaceuticals' Operating Leases fell 5.91% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 5.91%. This contributed to the annual value of $8.0 million for FY2024, which is 1192.06% up from last year.
  • Mirum Pharmaceuticals' Operating Leases amounted to $8.0 million in FY2024, which was up 1,192.06% from $617,000 recorded in FY2023.
  • Mirum Pharmaceuticals' Operating Leases' 5-year high stood at $8.0 million during FY2024, with a 5-year trough of $617,000 in FY2023.
  • For the 3-year period, Mirum Pharmaceuticals' Operating Leases averaged around $3.3 million, with its median value being $1.3 million (2022).
  • Per our database at Business Quant, Mirum Pharmaceuticals' Operating Leases plummeted by 50.91% in 2023 and then soared by 1,192.06% in 2024.
  • Yearly analysis of 5 years shows Mirum Pharmaceuticals' Operating Leases stood at $2.6 million in 2020, then decreased by 27.56% to $1.9 million in 2021, then plummeted by 33.95% to $1.3 million in 2022, then tumbled by 50.91% to $617,000 in 2023, then soared by 1,192.06% to $8.0 million in 2024.